
Biosynex to Acquire Chembio Diagnostics for $17.2M
NEW YORK – French rapid test maker Biosynex said late Tuesday that it has reached a definitive agreement to acquire Chembio Diagnostics for $17.2 million in cash. Under the deal, Biosynex

Thermo Fisher nears $45B in 2022 revenues, a 15% jump, despite two-thirds decline in COVID test sales
Despite its overall revenue growth, Thermo Fisher saw virtually no change—in either direction—for its organic revenues, which exclude the impacts of the company’s acquisitions and of changes in foreign exchange

Sherlock Biosciences to Acquire Sense Biodetection
NEW YORK – Sherlock Biosciences announced on Wednesday that it will acquire Cambridge, UK, molecular diagnostics company Sense Biodetection for undisclosed terms. The firms intend to pair Sherlock’s CRISPR, synthetic

Goldfinch Bio has its wings clipped, shutting down after 7 years
Goldfinch Bio’s swift curtain call comes less than three years after the company raised a $100 million series B. Goldfinch Bio, a 2020 Fierce Biotech Fierce 15 winner, is shutting

Celularity warns ‘substantial portion’ of staff about possible layoffs after reviewing cell therapy strategy
Celgene spinout Celularity has left an ax dangling over a “substantial portion” of its workforce. While the cell therapy firm is “hopeful” it can avoid significant layoffs, it has told many staffers

Guardant Health Lays off 7 Percent of Workforce
NEW YORK – Guardant Health has laid off approximately 7 percent of its workforce, the company confirmed on Wednesday, or about 130 individuals. According to terminated employees posting on LinkedIn,

Behind the deal: AstraZeneca’s eagerness for CinCor acquisition revealed in larger initial offer
AstraZeneca initially pitched an offer of $54 per share, double what the Big Pharma would ultimately pay for CinCor. AstraZeneca kicked off this year’s J.P.Morgan Healthcare Conference in style, announcing

Eitan Medical Opens Manufacturing Facility at Headquarters
An onsite manufacturing facility will allow the company to maintain full oversight of its production. Eitan Medical, a manufacturing company focused on advanced infusion therapy and drug delivery solutions, recently announced the

Caris Life Sciences nears $2B in total funding with $400M haul
The most recent addition to Caris’ offerings is the Assure molecular profiling assay, which sequences the entire genome to look for mutations that may be linked to cancer. After blowing

PAVmed, Lucid, Veris Axe Workforce by 20%
PAVmed and its subsidiaries, Lucid and Veris, will also implement a strategic plan that will hopefully lower quarterly cash-burn by 25%. PAVmed, a commercial-stage medical technology company, and its majority-owned

Gilead fosters growth with plans for new research center in California hometown
Gilead’s new research building is designed to include about 175,000 square feet of digitally enabled lab space. Gilead Sciences is expanding with a new research center that’s plotted in headquarters

Lucid Diagnostics Lays Off 20 Percent of Workforce in Business Reprioritization
NEW YORK – PAVmed and its subsidiaries Lucid Diagnostics and Veris Health announced on Tuesday that they have laid off 20 percent of their employees in an effort to lower

B+L Set to Acquire AcuFocus in Busy M&A Month
AcuFocus has developed the IC-8 Apthera intraocular lens (IOL), which was approved by FDA in July 2022. The deal volume in 2023 is already off to a strong start in

Illumina Could Face Hefty Fine Over Grail Acquisition
The San Diego, CA-based company is facing a fine because of closing the Grail acquisition without waiting for EU antitrust approval, according to a Reuters report. The fallout from Illumina’s

Verily narrows its focus, cutting device work and laying off 15% of staff
“We will center our strategy on closing the gap between research and care, and becoming the data and evidence backbone for precision health, with a focus on applying AI and